MAPT and Alzheimer disease: According to the revised “ABC” classification by the National Institute on Aging (NIA), AD-associated neuropathological changes (ADNPC) were classified as “intermediate” due to limited tau pathology (Braak stage IV; Figure 3A) despite extensive amyloid deposition (Thal phase 5, CERAD score C), including amyloid-β peptide deposits in the cerebellum (Figure 3B), as well as severe generalized CAA.